In addition, in early SSc-ILD, CCL18 has been shown to be a potential surrogate of response to anti IL-6 therapy; SSc-ILD patients treated with tocilizumab who experienced a minor functional decline also documented a major reduction in CCL18 [61]. Here, CCL18 is linked to systemic sclerosis.